123 related articles for article (PubMed ID: 32787337)
1. Repurposing Low-Molecular-Weight Drugs against the Main Protease of Severe Acute Respiratory Syndrome Coronavirus 2.
Gao J; Zhang L; Liu X; Li F; Ma R; Zhu Z; Zhang J; Wu J; Shi Y; Pan Y; Ge Y; Ruan K
J Phys Chem Lett; 2020 Sep; 11(17):7267-7272. PubMed ID: 32787337
[TBL] [Abstract][Full Text] [Related]
2. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB
Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297
[TBL] [Abstract][Full Text] [Related]
3. In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection.
Martorana A; Gentile C; Lauria A
Viruses; 2020 Jul; 12(8):. PubMed ID: 32722574
[TBL] [Abstract][Full Text] [Related]
4. Molecular Binding Mechanism and Pharmacology Comparative Analysis of Noscapine for Repurposing against SARS-CoV-2 Protease.
Kumar N; Sood D; van der Spek PJ; Sharma HS; Chandra R
J Proteome Res; 2020 Nov; 19(11):4678-4689. PubMed ID: 32786685
[TBL] [Abstract][Full Text] [Related]
5. Optimization Rules for SARS-CoV-2 M
Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
[TBL] [Abstract][Full Text] [Related]
6.
Sachdeva C; Wadhwa A; Kumari A; Hussain F; Jha P; Kaushik NK
OMICS; 2020 Oct; 24(10):568-580. PubMed ID: 32757981
[TBL] [Abstract][Full Text] [Related]
7. Computational insights into tetracyclines as inhibitors against SARS-CoV-2 M
Bharadwaj S; Lee KE; Dwivedi VD; Kang SG
Life Sci; 2020 Sep; 257():118080. PubMed ID: 32653520
[TBL] [Abstract][Full Text] [Related]
8. Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome-Coronavirus 2 In Vitro When Administered After Virus Infection.
Clementi N; Ferrarese R; Criscuolo E; Diotti RA; Castelli M; Scagnolari C; Burioni R; Antonelli G; Clementi M; Mancini N
J Infect Dis; 2020 Aug; 222(5):722-725. PubMed ID: 32559285
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
Goyal B; Goyal D
ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
[TBL] [Abstract][Full Text] [Related]
10. Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.
Yamaya M; Nishimura H; Deng X; Kikuchi A; Nagatomi R
Tohoku J Exp Med; 2020 May; 251(1):27-30. PubMed ID: 32448818
[TBL] [Abstract][Full Text] [Related]
11. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.
Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A
Molecules; 2020 May; 25(11):. PubMed ID: 32485894
[TBL] [Abstract][Full Text] [Related]
12. Biochemical screening for SARS-CoV-2 main protease inhibitors.
Coelho C; Gallo G; Campos CB; Hardy L; Würtele M
PLoS One; 2020; 15(10):e0240079. PubMed ID: 33022015
[TBL] [Abstract][Full Text] [Related]
13. Anti-SARS-CoV-2 Potential of Artemisinins In Vitro.
Cao R; Hu H; Li Y; Wang X; Xu M; Liu J; Zhang H; Yan Y; Zhao L; Li W; Zhang T; Xiao D; Guo X; Li Y; Yang J; Hu Z; Wang M; Zhong W
ACS Infect Dis; 2020 Sep; 6(9):2524-2531. PubMed ID: 32786284
[TBL] [Abstract][Full Text] [Related]
14. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
Zhu Y; Yu D; Yan H; Chong H; He Y
J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophore modelling of vanillin derivatives, favipiravir, chloroquine, hydroxychloroquine, monolaurin and tetrodotoxin as M
Law WY; Asaruddin MR; Bhawani SA; Mohamad S
BMC Res Notes; 2020 Nov; 13(1):527. PubMed ID: 33176880
[TBL] [Abstract][Full Text] [Related]
16. Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.
Theerawatanasirikul S; Kuo CJ; Phecharat N; Chootip J; Lekcharoensuk C; Lekcharoensuk P
Antiviral Res; 2020 Oct; 182():104927. PubMed ID: 32910955
[TBL] [Abstract][Full Text] [Related]
17. A Comprehensive Mapping of the Druggable Cavities within the SARS-CoV-2 Therapeutically Relevant Proteins by Combining Pocket and Docking Searches as Implemented in Pockets 2.0.
Gervasoni S; Vistoli G; Talarico C; Manelfi C; Beccari AR; Studer G; Tauriello G; Waterhouse AM; Schwede T; Pedretti A
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708196
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 RNA polymerase as target for antiviral therapy.
Buonaguro L; Tagliamonte M; Tornesello ML; Buonaguro FM
J Transl Med; 2020 May; 18(1):185. PubMed ID: 32370758
[TBL] [Abstract][Full Text] [Related]
19. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
20. A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study.
Novak J; Potemkin VA
Mol Divers; 2022 Oct; 26(5):2631-2645. PubMed ID: 35001230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
